Then, we validated the potential therapeutic activity of AR-C and SYRO in AML cells, by using AR-C and SYRO in combination, or not, with conventional anti-leukemia treatment and as compared to AC-73 treatment (22). The gene discussed is ARC; the disease is acute myeloid leukemia.